The US Food and Drug Administration has approved a new inhaled antibiotic called Cayston, a major breakthrough in treating lung infections caused by cystic fibrosis (CF) and the first inhaled antibiotic to receive US approval in over ten years.

Developed by Gilead Sciences, with support from the Cystic Fibrosis Foundation, Cayston offers a much-needed antibiotic alternative for patients who battle recurrent lung infections and develop resistance to existing antibiotics.

Cystic Fibrosis Foundation CEO Robert J Beall said that the approval of Cayston demonstrates that the drug development model is working and making a real difference in the lives of people with CF.

“We are delighted to have a new antibiotic in the arsenal to help fight the life-threatening infections associated with this disease, as we continue to push forward with other therapies that address the underlying cause of CF,” Beall said.

Cayston is the first CF drug to advance through the Cystic Fibrosis Foundation’s Therapeutics Development Program, which is designed to speed the creation of new CF therapies.

Cayston is administered with a new device called the Altera Nebulizer System, which allows patients to take the medicine in less than five minutes, a huge advantage over other treatments, which on average require a treatment regimen of three-to-four hours per day.